Skip to content

Radial Shockwave for Spasticity in Children With CP or ABI

Radial Shockwave Therapy With ShockMaster 300® to Reduce Spasticity in Children With CP or Acquired Brain Injury: a Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06909838
Enrollment
24
Registered
2025-04-04
Start date
2024-09-24
Completion date
2025-06-05
Last updated
2025-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spasticity Due to Cerebral Palsy, Spasticity Post-Traumatic Brain Injury

Keywords

Extracorporeal shockwave therapy, shockwave therapy, shock wave therapy, children, radial shockwave therapy

Brief summary

The goal of this clinical trial is to determine if radial Extracorporeal shockwave therapy (rESWT) reduces spasticity in children with Cerbral Palsy (CP) or traumatic brain injury (TBI). The main questions it aims to answer are: * Is it feasible to implement radial shockwave therapy in conventional physiotherapy plan in children with CP or TBI? * Is it safe and effective to use rESWT for reducing spasticity in children with CP or TBI? Participants will receive a 4 week therapy intervention, as add on to the conventional physio (usual care), including one rESWT session per week for a total of 4 sessions.

Interventions

DEVICEradial Extracorporeal shockwave therapy (rESWT)

4 rESWT interventions, with a one week interval, are added to the conventional treatment plan

OTHERConventional treatment

Usual conventional therapy, including physiotherapy, ergotherapy, hippotherapy,..

Sponsors

FRAME Jessa Ziekenhuis, Belgium
CollaboratorUNKNOWN
Gymna Uniphy
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* cerebral palsy or acquired brain injury * between 6-18 years old; * gross motor function classification ≥2; * experiencing spasticity in the lower limb (calf muscles, hip adductor muscles or hamstring muscles) and/or in the upper limb (biceps muscle, wrist flexor muscles, finger flexor muscles) with Modified Ashworth Scores (MAS) ≥1+.

Exclusion criteria

* recent (≤3 months) Botox injections or other recent (≤6 months) invasive intervention; * local infections or wounds; neuropathy; * severe organ dysfunction; * severe psychosocial dysfunction that would not allow adhering to protocol; * planned changes in medication dosage or medication scheme that might affect spasticity during a 4-month intervention and follow-up phase.

Design outcomes

Primary

MeasureTime frameDescription
Modified Ashworth ScaleChange from baseline to the end of intervention sessions at week 4The modified Ashworth scale is a muscle tone assessment scale used to assess the resistance experienced during passive range of motion. The scale is validated for use in various clinical populations to measure spasticity. The MAS score varies form 0 (no increase in tone) up to 4 (limb rigid in flexion or extension).

Secondary

MeasureTime frameDescription
Patient Specific Functional ScaleChange from baseline to the end of intervention sessions at week 4The PSFS focuses on the patient's opinion of their function, and requires the physiotherapist to ask the patient to list three activities that are limited by the condition for which they are seeking treatment. The current level of difficulty associated with the activities is rated on a 11 point scale, where 0 represents unable to perform activity and 10 represents able to perform at prior level.
passive Range Of MotionChange from baseline to the end of intervention sessions at week 4Passive range of motion (PROM) is the ROM that is achieved when a therapist exclusively causes movement of a joint and is usually the maximum range of motion that a joint can move. An increasing ROM in spasticity helps maintain or increase the extensibility of soft tissue and joints, reduces pain, improves function and can normalize muscle tone.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026